Understanding Quality-of-Life Impacts in Lung Cancer Via Social Listening from Patient and Caregiver Perspectives

2021 Year in Review: Non–Small-Cell Lung Cancer —December 29, 2021

Categories:

Lung Cancer

Patients and caregivers are increasingly turning to social media to learn about and share their disease-related experiences. Lung cancer is the most common cancer in the world, affecting more than 2 million people. This observational study used social listening to analyze social media trends to learn more about quality-of-life (QOL) impacts and perceptions in patients with advanced lung cancer.1

A study was undertaken by gathering retrospective data (June 2019 to May 2020) from 14 European countries’ open-access blogs, forums, and social networking sites. Using social media aggregator tools, conversations involving lung cancer and non–small-cell lung cancer (NSCLC)-specific phrases were retrieved. Automated relevancy algorithms and manual assessment were used to filter the data into a contextualized data set.1

Patients and caregivers were the key stakeholders in 1360 interactions, 100 of which were about QOL. The predominant QOL consequence (70%) was emotional strain, which was linked to all stages of the patient experience. Patients were overwhelmed by the amount and complexity of information available at the time of diagnosis, as well as disheartened by survival rates. Patients often felt stigmatized because of their smoking history, as if they were seen to be responsible for their illness. Fear and anxiety arose as a result of awaiting test results and relapse; the lack of appropriate postrelapse treatments added to the misery. Because of a lack of empathy and communication, some patients felt abandoned by physicians. Physical QOL issues, such as side effects and long-term physical handicap, were highlighted in 38% of talks. Muscle ache, dyspnea, and weariness were among the symptoms mentioned. Only 2% of conversations included the topic of social wellness. Nine percent (N = 539) of dialogues were about clinical outcomes where improved QOL was mentioned as a treatment goal.1

The greatest QOL consequence of lung cancer, according to this study, is mental burden, followed by physical effects. Despite the limits of social listening, this study adds to our understanding of the lung cancer experience and emphasizes patients’ desire for more medical empathy.1 From the caregiver perspective, studies have shown that their patients’ QOL has a greater impact on caregiver burden than lung cancer stage.2

References

  1. Montrone M, Chauhan J, Sagkriotis, et al. Understanding patient and caregiver perceptions of quality of life (QoL) impacts in lung cancer through social listening. Ann Oncol. 2021;32(suppl 5):S1024.
  2. Borges EL, Franceshini J, Degani Costa LH, et al. Family caregiver burden: the burden of caring for lung cancer patients according to the cancer stage and patient quality of life. J Bras Pneumol. 2017;43:18-23.
Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country